| 田文霞1，赵玲2，孟宪霞3.免疫卡控点PD-1/PD-L1在肿瘤免疫中的研究进展[J].中国医药科学,2022,(8):64-67 基金项目: |
| 免疫卡控点PD-1/PD-L1在肿瘤免疫中的研究进展 |
| Advances in the study on the application of immune checkpoint PD-1/PD-L1 in tumor immunity |
| |
| DOI： |
| 中文关键词: PD-1；PD-L1；肿瘤免疫；免疫抑制剂 |
| 英文关键词:PD-1; PD-L1; Tumor immunity; Immunosuppressant |
| 作者 | 单位 | | 田文霞1，赵玲2，孟宪霞3 | 1.济南市卫生健康宣传教育中心综合科，山东济南 250000；2.济南市人民医院康复医学科，山东济南 251199；3.济南市血液供保中心检验科，山东济南 250000 |
|
| 摘要点击次数: 1036 |
| 全文下载次数: 2821 |
| 中文摘要: |
| [摘要] 肿瘤的发病率和病死率逐年升高，而现有的治疗手段有限。目前免疫卡控点抑制剂在多种肿瘤的治疗中广泛开展，免疫卡控点程序性死亡分子-1（PD-1）/PD-1配体（PD-L1）信号传导通路在肿瘤免疫抑制中发挥重要作用，PD-1/PD-L1通路可通过抑制免疫细胞活性和增强肿瘤细胞的免疫耐受，使肿瘤细胞发生免疫逃逸。近年来，针对PD-1/PD-L1抑制剂的临床研究取得突破性进展。本文就PD-1及其配体PD-L1的生物学特性、作用机制及在多种肿瘤中的表达、免疫机制的研究进展做一综述，并对PD-1/PD-L1在肿瘤治疗中的应用前景进行展望。 |
| 英文摘要: |
| [Abstract] The morbidity and mortality in individuals caused by tumors are increasing year by year but with limited available treatments. Currently, immune checkpoint inhibitors are being widely applied in the treatment of a variety of tumors. The immune checkpoint programmed death-1 (PD-1) /PD-1 ligand (PD-L1) signaling pathway plays an important role in tumor immunosuppression, and the PD-1/PD-L1 signaling pathway can cause immune escape of tumor cells by inhibiting immune cell activity and enhancing immune tolerance of tumor cells. In recent years, breakthroughs have been made in clinical studies targeting PD-1/PD-L1 inhibitors. Based on this, this paper reviews the biological properties, mechanism of action, immune mechanisms and expression of PD-1/PD-L1 in a variety of tumors as well as the latest study advances, and provides an outlook on the application of PD-1/PD-L1 in tumor therapy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
.jpg)